The drug, Takhzyro, is expected to bring in blockbuster sales for
Shire, and is important to Japan's Takeda Pharmaceutical Co Ltd,
which plans to buy the Dublin-based rare disease specialist for $62
billion.
The monoclonal antibody, previously known by its chemical name
lanadelumab, was approved
https://www.fda.gov/Drugs/Drug
Safety/ucm618261.htm?utm_campaign=FDA%20approves%20new%20treatment%20for%20hereditary%20angioedema%20%28HAE%29&utm_medium=
email&utm_source=Eloqua to treat patients with types I and II
hereditary angioedema (HAE), a disease that affects about 1 in
50,000.
[to top of second column] |
![](http://archives.lincolndailynews.com/2018/Aug/24/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
There are only a handful of treatments available for HAE, including
some from Shire. The disease affects people who have low levels of a
certain protein and results in episodes of severe swelling in
different areas such as the stomach, limbs, face and throat.
(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |